Skip to main content

Specialty Pharmacy

  • Steven Miesowicz appointed to new role at Diplomat Specialty Pharmacy

    FLINT, Mich. Diplomat Specialty Pharmacy has promoted Steven Miesowicz to VP human resources, planning and government relations, the company said Monday.

     

    Miesowicz previously served as the company’s senior director for human resources and as a business management consultant. He had a large role in securing the Michigan Economic Growth Authority tax credit that the company received in connection with the relocation to its new Flint, Mich., headquarters.

     

     

  • Amgen's Xgeva receives FDA approval

    SILVER SPRING, Md. — The Food and Drug Administration has approved a treatment for preventing skeletal injuries in patients whose cancer has spread to the bone.

     

    The FDA announced Friday the approval of Thousand Oaks, Calif.-based biotech company Amgen’s Xgeva (denosumab) for bone metastases.

     

     

  • Report: J&J subsidiary, government officials seek to block HIV generic

    NEW YORK — Johnson & Johnson and the U.S. government are suing two generic drug makers to stop them from launching a generic drug for HIV, according to published reports.

     

    Bloomberg reported Thursday that Tibotec, a subsidiary of J&J, and the government were separately suing Mylan and Lupin over a generic version of the drug Prezista (darunavir ethanolate), alleging patent infringement.

     

     

  • Pfizer on kidney cancer drug: Extends lives of patients

    NEW YORK — Pfizer got promising results from a late-stage clinical trial of a cancer treatment, the drug maker said Friday.

     

    Pfizer announced results of the phase-3 “AXIS 1032” trial of the kidney cancer drug axitinib, saying that it “significantly” extended the lives of patients with advanced renal cell carcinoma compared with Nexavar (sorafenib), made by Bayer HealthCare and Onyx Pharmaceuticals.

     

     

  • Express Scripts establishes specialty benefits organization

    ST. LOUIS — Pharmacy benefit manager Express Scripts has created what it calls the industry’s most comprehensive specialty benefits organization, the company announced Thursday.

     

  • FDA panel recommends approval for lupus drug Benlysta

    ROCKVILLE, Md. A decision by a Food and Drug Administration advisory committee could pave the way for the first new drug to treat lupus in decades.

     

    The FDA’s Arthritis Advisory Committee voted 13-2 Tuesday to recommend approval for Benlysta (belimumab), a drug for systemic lupus erythematosus made by British drug maker GlaxoSmithKline and U.S.-based Human Genome Sciences, the two companies announced. Lupus is an inflammatory disorder that affects internal organs, joints and skin and, in its severest forms, can be fatal.

     

  • FDA advisory committee recommends expanded use of Gardasil

    WHITEHOUSE STATION, N.J. — A Food and Drug Administration advisory committee has recommended expanded approval of a vaccine for genital warts.

    Merck announced Wednesday that the FDA Vaccines and Related Biological Products Advisory Committee recommended approval of Gardasil (human papillomavirus quadrivalent [types 6, 11, 16 and 18] vaccine, recombinant) for males and females ages 9 to 26 years to prevent anal cancer and anal intraepithelial neoplasia, both diseases that result from infection by the human papillomavirus.

  • COPD patients express hardships in new GSK study

    RESEARCH TRIANGLE PARK, N.C. Patients living with chronic obstructive pulmonary disease said the illness prevented them from living life to its fullest, according to research conducted by drug maker GlaxoSmithKline.

     

X
This ad will auto-close in 10 seconds